Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Macrophage IL-1β turns meningeal fibroblasts into inflammatory amplifiers in pneumococcal infection.

Frontiers in immunology·2026

Same author

Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.

German medical science : GMS e-journal·2025

Same author

Pharmacologic depletion of border-associated macrophages worsens disease in a mouse model of meningitis.

Acta neuropathologica communications·2025

Same author

Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.

Cancer cell·2025

Same author

Effective surveillance of acute COVID-19 using a cost- and labor-efficient approach: a paradigm for the longitudinal monitoring of respiratory infections in larger cohorts.

Infection·2025

Same author

Videodistraction to reduce agitation in elderly patients in the emergency department: an open label parallel group randomized controlled trial.

European journal of emergency medicine : official journal of the European Society for Emergency Medicine·2024

Search research articles

Related Experiment Video

Updated: Mar 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Dramatic reduction of mortality in pneumococcal meningitis.

Grete Buchholz¹, Uwe Koedel¹, Hans-Walter Pfister¹

¹Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistr. 15, 81377, Munich, Germany.

Critical Care (London, England)

|October 8, 2016

Summary

Advances in treating pneumococcal meningitis have drastically reduced mortality rates. However, many survivors experience long-term complications, highlighting the need for improved adjunctive therapies.

Keywords:

Bacterial meningitis CNS infection Intracranial complications Neurocritical care Pneumococcal meningitis Streptococcus pneumoniae

More Related Videos

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Related Experiment Videos

Last Updated: Mar 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Area of Science:

Neurology
Infectious Diseases
Clinical Medicine

Background:

Acute bacterial meningitis remains a life-threatening condition.
Pneumococcal meningitis is a significant cause of mortality and morbidity.
Effective treatment strategies are crucial for patient outcomes.

Purpose of the Study:

To evaluate clinical characteristics of pneumococcal meningitis patients.
To compare outcomes between contemporary and historical patient cohorts.
To identify areas for therapeutic improvement.

Main Methods:

Retrospective observational study.
Analysis of consecutively admitted patients (2003-2015).
Comparison with a historical cohort (1984-2002).

Main Results:

Mortality significantly decreased from 24.1% to 5.5%.
Intracranial complications affected 50% of patients.
Most complications, except ischemic stroke, did not correlate with poor outcomes.

Conclusions:

Treatment advances have dramatically reduced pneumococcal meningitis mortality.
A significant proportion of survivors have incomplete recovery.
Further research into adjunctive treatments is essential.